• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 36
  • 15
  • 8
  • 7
  • 4
  • 1
  • 1
  • Tagged with
  • 90
  • 90
  • 21
  • 20
  • 18
  • 17
  • 13
  • 13
  • 13
  • 12
  • 11
  • 11
  • 11
  • 11
  • 11
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
61

Étude moléculaire des mécanismes d’action de potentiateurs du canal CFTR sur le canal KCa3.1

Longpré-Lauzon, Ariane 08 1900 (has links)
Les cellules épithéliales des voies aériennes respiratoires sécrètent du Cl- via le canal CFTR. La fibrose kystique est une maladie génétique fatale causée par des mutations de ce canal. La mutation la plus fréquente en Amérique du Nord, ∆F508, met en péril la maturation de la protéine et affecte les mécanismes d’activation du canal. Au cours des dernières années, plusieurs molécules ont été identifiées par criblage à haut débit qui peuvent rétablir l’activation de protéines CFTR mutées. Ces molécules sont nommées potentiateurs. Les canaux K+ basolatéraux, dont KCa3.1, jouent un rôle bien documenté dans l’établissement d’une force électromotrice favorable à la sécrétion de Cl- par CFTR dans les cellules épithéliales des voies aériennes respiratoires. Il a par exemple été démontré que l’application de 1-EBIO, un activateur de KCa3.1, sur des monocouches T84 résulte en une augmentation soutenue de la sécrétion de Cl- et que cette augmentation était réversible suite à l’application de CTX, un inhibiteur de KCa3.1(Devor et al., 1996). Dans le cadre d’une recherche de potentiateurs efficaces en conditions physiologiques et dans un contexte global de transport trans-cellulaire, il devient essentiel de considérer les effets des potentiateurs de CFTR sur KCa3.1. Une caractérisation électrophysiologique par la méthode du patch clamp et structurelle via l’utilisation de canaux modifiés par mutagenèse dirigée de différents potentiateurs de CFTR sur KCa3.1 fut donc entreprise afin de déterminer l’action de ces molécules sur l’activité de KCa3.1 et d’en établir les mécanismes. Nous présentons ici des résultats portant sur les effets sur KCa3.1 de quelques potentiateurs de CFTR possédant différentes structures. Un criblage des effets de ces molécules sur KCa3.1 a révélé que la genisteine, le SF-03, la curcumine et le VRT-532 ont des effets inhibiteurs sur KCa3.1. Nos résultats suggèrent que le SF-03 pourrait agir sur une protéine accessoire et avoir un effet indirect sur KCa3.1. La curcumine aurait aussi une action inhibitrice indirecte, probablement via la membrane cellulaire. Nos recherches sur les effets du VRT-532 ont montré que l’accessibilité au site d’action de cette v molécule est indépendante de l’état d’ouverture de KCa3.1. L’absence d’effets inhibiteurs de VRT-532 sur le mutant constitutivement actif V282G indique que cette molécule pourrait agir via l’interaction CaM-KCa3.1 et nécessiter la présence de Ca2+ pour agir. Par ailleurs, un autre potentiateur de CFTR, le CBIQ, a des effets potentiateurs sur KCa3.1. Nos résultats en canal unitaire indiquent qu’il déstabilise un état fermé du canal. Nos travaux montrent aussi que CBIQ augmente la probabilité d’ouverture de KCa3.1 en conditions sursaturantes de Ca2+, ainsi que son affinité apparente pour le Ca2+. Des expériences où CBIQ est appliqué en présence ou en absence de Ca2+ ont indiqué que l’accessibilité à son site d’action est indépendante de l’état d’ouverture de KCa3.1, mais que la présence de Ca2+ est nécessaire à son action. Ces résultats sont compatibles avec une action de CBIQ déstabilisant un état fermé du canal. Finalement, des expériences en Ba2+ nous ont permis d’investiguer la région du filtre de sélectivité de KCa3.1 lors de l’action de CBIQ et nos résultats pointent vers une action de CBIQ dans cette région. Sur la base de nos résultats nous concluons que CBIQ, un potentiateur de CFTR, aurait un effet activateur sur KCa3.1 via la déstabilisation d’un état fermé du canal à travers une action sur sa ‘gate’ au niveau du filtre de sélectivité. De plus, les potentiateurs de CFTR ayant montré des effets inhibiteurs sur KCa3.1 pourraient agir via la membrane ou via une protéine accessoire du canal ou sur l’interaction CaM-KCa3.1. Dans l’optique de traitements potentiels de la fibrose kystique, nos résultats indiquent que le CBIQ pourrait être un potentiateur efficace pusiqu’il est capable de trimuler à la fois KCa3.1 et CFTR. Par contre, dans les cas du VRT-532 et du SF-03, une inhibition de KCa3.1 pourraient en faire des potentiateurs moins efficaces. / Airway epithelial cells are the site of Cl- secretion through CFTR. Cystic fibrosis is a fatal genetic disease caused by mutations in CFTR. The most frequent mutation in North America (∆F508) results in impaired maturation and altered channel gating of the protein. In the last years, several small molecules were identified by high throughput screening that could restore mutated CFTR function. Compounds addressing CFTR gating defects are referred to as potentiators. The basolateral K+ channel KCa3.1 has been documented to play a prominent role in establishing a suitable driving force for CFTR-mediated Clsecretion in airway epithelial cells. It has been shown, for example, that the application of 1-EBIO on T84 monolayers results in a sustained increase of Clsecretion and that this current can be reversed by application of CTX, a KCa3.1 inhibitor (Devor et al., 1996). Thus, in a global approach of transepithelial transport, the research for physiologically relevant CFTR potentiators should also consider their effects on the KCa3.1 channel. Electrophysiological patch clamp measurements and channel structural modification by site directed mutagenesis were used to characterize the action of CFTR potentiators on KCa3.1 and study their molecular mode of action. In this work we present results on the effects on KCa3.1 of several CFTR potentiators of different structures. We observed that the CFTR potentiators genistein, curcumin, SF-03 and VRT-532 could inhibit KCa3.1 activity at concentrations known to activate CFTR. Our results suggest that SF- 03 could act indirectly on KCa3.1 through a mechanism involving an accessory protein. Curcumin would also have an indirect inhibitory effect, probably mediated by the plasma membrane, as documented for other ion channels. A detailed study of VRT-532 revealed that this molecule has access to its binding site in a state independent manner, and is poorly effective on the V282G mutant of KCa3.1, which is constitutively active. These results suggest that VRT-532 could act through the CaM/KCa3.1 complex and require the presence of Ca2+ to inhibit channel activity. In contrast, CBIQ, another CFTR potentiator, succeeded to activate KCa3.1. Our results in single channel show that CBIQ vii destabilizes a non conducting state of the channel. We also showed that this molecule increases the apparent Ca2+ affinity as well as the channel open probability, even in saturating Ca2+ conditions. Experiences in which Ba2+ was used as a probe were also performed to determine if the action mechanism of CBIQ involves an effect on the selectivity filter. Our results showed that Ba2+ could displace CBIQ from its interacting site, suggesting that the increases in channel activity induced by CBIQ could result from a change in the energetics of the channel at the level of the selectivity filter. On the basis of our results, we conclude that CBIQ, a CFTR potentiator, could activate KCa3.1 by destabilizing a non conducting state of the channel, probably through an action near the selectivity filter region. Also, CFTR potentiators having an inhibitory effect on KCa3.1 are likely to act through the plasmic membrane, the CaM/KCa3.1 interaction or an accessory protein of the channel. In a perspective of future treatments for CF, our results indicate that CBIQ could be an efficient potentiator since this product stimulates KCa3.1 as well as CFTR. Conversly, the VRT-532 and SF-03 could be less efficient than on CFTR alone, due to their inhibition of KCa3.1.
62

Etudes biochimiques, structurales et fonctionnelles du complexe MARS de Toxoplasma gondii, une nouvelle cible thérapeutique / Biochemical, structural and functional studies of the Toxoplasma gondii MARS complex, a novel therapeutic target

Murat, Jean-Benjamin 25 September 2014 (has links)
Toxoplasma gondii, parasite digestif des Félidés, est l'agent de la toxoplasmose, maladie pouvant être grave voire mortelle en cas d'infection fœtale ou chez l'immunodéprimé. Les traitements actuellement disponibles permettent de prévenir ou traiter la plupart des cas, mais peuvent présenter un risque d'effets indésirables relativement sévères et ne permettent pas de détruire les kystes responsables de l'infection chronique et du risque de réactivation chez l'immunodéprimé. Les aminoacyl-ARNt synthétases (aaRS) sont des enzymes essentielles au mécanisme de traduction, où elles participent au chargement d'un acide aminé sur une molécule dédiée d'ARN de transfert, une étape initiale du processus de synthèse protéique. Un gène codant une protéine homologue de p43, un partenaire protéique de certaines aaRS chez les Eucaryotes supérieurs, a été identifié dans le génome de T. gondii. La localisation subcellulaire post-invasion de Tg-p43 montre qu'il ne s'agit pas d'une cytokine sécrétée, contrairement à son homologue humaine ; au contraire, son immunopurification a révélé son association à quatre aaRS, les Méthionyl-, Glutamyl-, Glutaminyl- et Tyrosyl-ARNt synthétases, qui constituent donc le premier complexe multi-aaRS (MARS) décrit chez les parasites Apicomplexes, de localisation exclusivement cytoplasmique. La présence inattendue de la Tyrosyl-ARNt synthétase soulève plusieurs questions sur le plan de l'organisation et de l'assemblage du complexe. Des images de microscopie électronique et des analyses biochimiques soulignent l'hétérogénéité et la structure relâchée du complexe et confirment les récentes données issues des complexes MARS purifiés chez d'autres organismes. L'inactivation du gène Tg-p43 n'induit pas de modifications phénotypiques majeures (capacité d'invasion, prolifération) ni de diminution de la virulence ou de la kystogénèse en modèle murin. Les résultats sur la caractérisation du MARS ont été complétés par une approche thérapeutique. Un criblage in vitro de candidats-médicaments présélectionnés in silico pour inhiber la Glutaminyl-ARNt synthétase toxoplasmique a permis de mettre en évidence un composé parasitostatique, inhibiteur de la croissance des tachyzoïtes, avec une toxicité sur les cellules hôtes in vitro relativement faible. Ce travail de thèse pose les bases moléculaires et structurales du complexe MARS chez T. gondii. Il permet également d'aborder dans une certaine mesure l'histoire évolutive de ce complexe. Sa fonction biologique reste cependant un mystère ; le rôle de Tg-p43 dans le contrôle post-transcriptionnel, voire d'autres fonctions biologiques, est probablement trop subtil pour être mesuré dans nos conditions expérimentales. Le versant thérapeutique de ce travail constitue une étude préliminaire pouvant servir de point de départ pour la recherche de médicaments anti-toxoplasmiques ciblant les aaRS, qui constituent assurément des cibles thérapeutiques intéressantes. / Toxoplasma gondii, a parasite of felids gut, is responsible for toxoplasmosis, a disease that can induce severe sequelae or death in the foetus or immune-depressed patients. Currently available treatments can prevent or cure most of the cases, but are at risk for side effects and cannot suppress cysts, which cause the chronic disease and are responsible for disease when the immune status is altered. Aminoacyl-tRNA synthetases (aaRS) are essential for translation, by charging tRNA with cognate aminoacids, a preliminary step of the protein synthesis process.A gene coding for a protein homologous to p43 (which interacts with a subset of aaRSs in higher eukaryotes) was identified in the genome of T. gondii. Following its epitope tagging, we show that Tg-p43 is not secreted nor exported beyond the vacuole as a cytokine, as it is for its human counterpart; however, biochemical analysis of the Tg-p43 interactome reveals four aaRSs as interacting partners, namely Methionyl-, Glutamyl-, Glutaminyl- and Tyrosyl-tRNA synthetases. This is the first description of the multi-aaRS (MARS) complex in the Apicomplexa phylum; it is strictly localized in the parasite cytoplasm. The unexpected presence of the Tyrosyl-tRNA synthetase in the complex raises several questions about how the complex is organised and assembled, and also evolved. Electronic microscopy along with size exclusion chromatography shows heterogeneity and loose structure of the complex, similarly to recent data characterizing higher eukaryotic complexes. Disruption of the complex by knocking-out of the gene Tg-p43 does not induce detectable phenotypic modification, nor alterations of the virulence and cystogenesis in a murine model.Alongside the study on the MARS complex, we used an in silico approach to screen for new compounds to inhibit T. gondii Glutaminyl-tRNA synthetase. We thus identified one parasitostatic compound that was able to significantly slow down parasite growth while having a relatively low in vitro toxicity against the human host cell. The function of the MARS in T. gondii still remains unknown; the role of Tg-p43 in the post-transcriptional control or any other biological function is probably too subtle to be measured under our experimental conditions. However, our data help to some extent to better measure the evolutionary history of the MARS family. The therapeutic side of this work, although preliminary, may serve as a base for anti-T. gondii drug discovery focusing on aaRS inhibitors, which are obviously good candidate targets.
63

Methods for Detection of Small Molecule-Protein Interactions

January 2015 (has links)
abstract: Detection of molecular interactions is critical for understanding many biological processes, for detecting disease biomarkers, and for screening drug candidates. Fluorescence-based approach can be problematic, especially when applied to the detection of small molecules. Various label-free techniques, such as surface plasmon resonance technique are sensitive to mass, making it extremely challenging to detect small molecules. In this thesis, novel detection methods for molecular interactions are described. First, a simple detection paradigm based on reflectance interferometry is developed. This method is simple, low cost and can be easily applied for protein array detection. Second, a label-free charge sensitive optical detection (CSOD) technique is developed for detecting of both large and small molecules. The technique is based on that most molecules relevant to biomedical research and applications are charged or partially charged. An optical fiber is dipped into the well of a microplate. It detects the surface charge of the fiber, which does not decrease with the size (mass) of the molecule, making it particularly attractive for studying small molecules. Third, a method for mechanically amplification detection of molecular interactions (MADMI) is developed. It provides quantitative analysis of small molecules interaction with membrane proteins in intact cells. The interactions are monitored by detecting a mechanical deformation in the membrane induced by the molecular interactions. With this novel method small molecules and membrane proteins interaction in the intact cells can be detected. This new paradigm provides mechanical amplification of small interaction signals, allowing us to measure the binding kinetics of both large and small molecules with membrane proteins, and to analyze heterogeneous nature of the binding kinetics between different cells, and different regions of a single cell. Last, by tracking the cell membrane edge deformation, binding caused downstream event – granule secretory has been measured. This method focuses on the plasma membrane change when granules fuse with the cell. The fusion of granules increases the plasma membrane area and thus the cell edge expands. The expansion is localized at the vesicle release location. Granule size was calculated based on measured edge expansion. The membrane deformation due to the granule release is real-time monitored by this method. / Dissertation/Thesis / Doctoral Dissertation Electrical Engineering 2015
64

Avaliação das atividades anticarie e antiproliferativa da 7-epiclusianona isolada da planta do genero Rheedia / Anti-carie and antiproliferative effect of 7-epiclusianone, isolated from Rheedia genus plant

Murata, Ramiro Mendonça 21 February 2008 (has links)
Orientador: Pedro Luiz Rosalen / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba / Made available in DSpace on 2018-08-10T01:12:55Z (GMT). No. of bitstreams: 1 Murata_RamiroMendonca_D.pdf: 1464696 bytes, checksum: b1ab3aaf5f8165d118a09db632816bc8 (MD5) Previous issue date: 2008 / Resumo: As plantas medicinais têm sido utilizadas em várias áreas da saúde como fonna alternativa de tratamento e prevenção de doenças. Conseqüentemente, muitos agentes de origem natural vêm sendo explorados, nas últimas décadas, devido as suas possíveis ações farmacológicas. Dentre os produtos naturais que se destacam estão os compostos da planta do gênero Rheedia, da família Guttiferae, que têm ações comprovadas contra várias doenças. Assim, o objetivo deste trabalho foi avaliar o potencial antimicrobiano, anticárie e antiproliferativo da 7-epiclusianona (7-epi), benzofenona isolada das plantas do gênero Rheedia. Para isso, foram realizados quatro estudos, cujos objetivos foram: (l) Analisar a influência da 7-epi na fonnação de biofilmes de Streptococcus mutans UAl59 em discos de hidroxiapatita, na queda de pH glicolítico e seu efeito na translocação de prótons pela atividade da F-ATPase. Além disso, foram realizados estudos para analisar seu efeito na atividade de glucosiltransferase (GTF) B e C; (2) Detenninar a influência da 7-epi, associada ao flúor, na composição de biofilmes de S. mutans e a atividades anticárie da 7 epi utilizando modelo experimental de cárie dental em ratos; (3) O efeito antimicróbico da 7-epi sobre o crescimento dos estreptococos do grupo mutans e (4) Avaliar o potencial antiproliferativo da 7-epi contra células derivadas de tumores malignos humanos. No estudo 1, a 7-epi reduziu a produção de ácidos orgânicos e a atividade da F-ATPase (61,1 %:t3,O). O composto também foi um potente inibidor da atividade de GTFs (85% de inibição). Nos biofilmes, o peso seco e a quantidade de polissacarídeos insolúveis também foram significativamente reduzidos. No estudo 2, a quantidade de polissacarídeos solúveis, insolúveis e intracelulares em biofilmes, bem como a incidência e a severidade de cárie em superfície lisa e sulco foram significativamente reduzidos pela 7-epi associada ao flúor (p<0,05). No estudo 3, 7-epi apresentou atividade antimicrobiana (CIM entre 2,5-5 Jlg/mL e CBM entre 10-20 Jlg/mL) em baixas concentrações. No estudo 4, a 7-epi apresentou atividade antiproliferativa. Para as células cancerígenas de melanoma (UACC-62), mama resistente (NCI-ADR), ovário (OVCAR) e pulmão (NCI-460) a 7-epi demonstrou-se mais potente que o controle positivo (doxorubicina). Desta forma, concluímos que a 7-epi possui atividade antimicrobiana, anticárie e antiproliferativa, sendo um promissor agente para a prevenção da cárie dental e com potencial atividade anticâncer / Abstract: Considering the great use of plants as medicinal substances in the popular medicine, it is critical to investigate their biological and chemical properties in order to not only help to enhance our understanding of the therapeutic potential of these natural products, but also how to make them more effective pharmacological agents. The enormous biodiversitiy of Brazil flora appears as an important source of new pharmacological agents. In this way, Rheedia genus showed the presence of flavonoids, xanthones and polyprenylated benzophenones with proved actions against important pathogens Overall, aim of this study was to evaluate the antimicrobial and atitumoral effect of the 7 -epiclusianone, isolated compound of the Rheedia genus planto Therefore, four studies were carried out. In study 1, the influence of 7-epiclusianone was evaluated on glucans production by purified glucosyltransferases (GTFs), on membrane-associated F-ATPase, on glycolytic activities and insoluble glucans composition/acidogenicity of S. mutans biofilmes. In study 2, the influence of 7-epiclusianone, alone or in combination with fluoride, on S. mutans biofilms and caries development in vivo was evaluated. In study 3, the ant microbial activity of the 7-epiclusianone was assessed by determination of minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) against S. mutans. In study 4, the influence of 7 -epiclusianone in a differential antiproliferative activity against a human cancer celllines. In study 1, the synthesis of glucans by glucosyltransferases B and C was remarkably reduced by 7-epiclusianone showing more than 80% inhibition of enzymatic activityat a concentration of 100 ~g/m1. The glycolytic pH-drop by S. mutans cells was also disrupted by 7-epiclusianone; an effect that can be attributed, in part, to inhibition of F-ATPase activity (61.1:t3.0 % inhibition at 100/lg/mL). The extracelIular insoluble polysaccharide concentration and acidogenicity of the biofilms were significant1y reduced by the test agent (P<0.05). In study 2, biofilms treated with 7-epiclusianone, alone or in combination with F, displayed less biomass and insoluble glucans than the positive control (tluoride) (p<0.05). The biological effect of 7-epiclusianone was great1y enhanced when used in combination with F. Furthermore, the combination of 7-epiclusianone with F was highlyeffective in preventing caries development in rats. In study 3, 7-epiclusian one was effective in inhibiting the growth of S. mutans (MIC 2.5-5 Ilg/ml and MBCIO-20 Ilg/ml). In study 4, 7 -epiclusianone displayed significant cytotoxic activity for alI celIlines. The ICso, half maximal inhibitory concentration, of 7-epiclusianone was significantly more potent positive control (doxorubicin) against melanoma (UACC-62), breast-resitant (NCI-ADR), ovarian (OVCAR), and lung (NCI-460) celIs. In conclusion, 7-epiclusianone have relevant antimicrobial and atiproliferative activity and are promising anti-caries and antitumoral agents / Doutorado / Farmacologia, Anestesiologia e Terapeutica / Doutor em Odontologia
65

Estudo do efeito da fração BRVD obtida a partir da própolis brasileira tipificada, na proliferação de células tumorais / Study of fraction BRVD effects gotten by tipificated Brazilian própolis, in the proliferation of tumorais cells

Martha Silveira e Costa 17 September 2007 (has links)
A própolis, um produto natural derivado de resinas de plantas coletadas por abelhas, foi usada por milhares de anos na medicina tradicional pelo mundo inteiro. Neste estudo, investigamos o efeito de uma fração da própolis vermelha brasileira (BRVD), no crescimento das células de melanoma murino (B16F10), das linhagens hematológicas humanas (HL-60 e K562), e de fibroblastos humanos (MCR-5 e FP). Após a análise preliminar de várias frações da própolis BRV, encontramos que a Fração BRVD inibiu fortemente o crescimento das células de uma maneira dose-tempo dependente pela necrose. Os resultados mostraram que essa fração induz eficazmente um efeito citotóxico em todas as linhagens estudadas, com média da IC50 em torno de 30 g/mL em 24 h de exposição. Estes resultados sugerem que a atividade antitumor da fração BRVD ocorre com a indução de necrose e os compostos dessa fração podem ser úteis como um agente contra o câncer / Propolis, a natural product derived from plant resins collected by honeybees, has been used for thousands of years in traditional medicine all over the world. In this study we have investigated the effect of some fractions from red Brazilian propolis on the growth of murine melanoma cell ( B16/F10), human hematological cells ( HL-60 and K562), and human fibroblasts cells (MCR-5 and FP). We found that BRVD strongly inhibited the growth of the cells in a dose- and time-dependent through induction of necrosis. Our results showed that BRVD effectively induced a cytotoxic effect on all cell lines studied, with IC50 average about 30 g/mL for 24 h of exposition. These results suggest that the antitumor activity of BRVD from red Brazilian propolis occurs through the induction of necrosis and its compounds may be useful as a anticancer agent
66

O papel pró-apoptótico da fosfoetanolamina sintética na formulação lipossomal DODAC na via envolvida na quimioresistência de células de câncer de mama / The pro-apoptotic role of synthetic phosphoethanolamine in the liposomal dodac formulation in the pathway involved in the chemoresistance of breast cancer cells

Antenor Pereira Bonfim Neto 24 August 2018 (has links)
A Fosfoetanolamina sintética (FOS) é uma molécula análoga aos fosfolipídios de membrana celular com propriedades antitumorais, antiinflamatórias e antiproliferativas. Nosso grupo de pesquisa desenvolveu diversos estudos com a FOS mostrando resultados satisfatórios quanto à sua eficácia antitumoral. Neste estudo foram avaliados os efeitos antitumorais in vitro da Fostoetanolamina e da formulação lipossomal DODAC/FOS em linhagem de carcinoma de mama murino (4T1). Os efeitos da citotoxicidade da FOS na linhagem tumoral 4T1 foi avaliado pela determinação da viabilidade celular pelo teste colorimétrico MTT e os valores obtidos da IC50% foram de 40mM e 20mM nos períodos de 24 e 48 horas, respectivamente. Com o tratamento com o lipossoma DODAC vazio nas células 4T1 a IC50% foi de 0,5 mM e 0,09 nos períodos de 6 e 12 horas, respectivamente e com o tratamento com a formulação lipossomal DODAC/Pho-s a IC50% de 0,78mM em 6 horas e 0,17mM em 12 horas de tratamento. A produção de radicais livres lipoperoxidados foi avaliada pela formação do TBARS em células 4T1, tratadas por 24 horas com Pho-s, mostrando diferença significativa a partir de 30mM e 1,6mM com o lipossoma DODAC vazio, não havendo diferença estatística no grupo DODAC/FOS. As alterações nas distribuições das populações celulares nas fases do ciclo celular avaliadas por citometria de fluxo mostraram um aumento do DNA fragmentado após 12 e 24 horas e diminuição nas outras fases do ciclo. As alterações nos arranjos celulares foram avaliadas por meio da marcação com os fluorocromos acridine-orange e rodamina 123 por microscopia confocal a laser, no qual foi observada a mudança na morfologia, fragmentação de membranas e perdas da projeção de prolongamentos citoplasmáticos. A indução de células em senescência foi avaliada pela atividade enzimática com a enzima ?-galactosidase, mostrando células senescente apenas na concentração de 20mM. A atividade apoptótica das células tumorais de mama foi avaliada pela Anexina V/PI, mostrando um aumento, principalmente, da apoptose tardia em todos os tratamentos. Diversos marcadores de controle e progressão do ciclo celular, stress, angiogênese e receptores hormonais e o potencial mitocondrial foram avaliados por citometria de fluxo. Os resultados mostraram um aumento na expressão das proteínas ligadas com a apoptose e morte celular e diminuição geral das proteínas que participam dos processos de progressão do ciclo celular e proliferação celular, além das proteínas anti-apoptóticas, o que demonstra o seu potencial antitumoral / Synthetic Phosphoethanolamine (FOS) is a analogous molecule to cell membrane phospholipids with antitumoral, anti-inflammatory and antiproliferative properties. Our research group has developed several studies with FOS showing satisfactory results regarding its antitumor efficacy. In this study we evaluated the in vitro antitumor effects of Fostoethanolamine and the DODAC/FOS liposomal formulation in murine breast carcinoma (4T1) line. The effects of the FOS cytotoxicity on the 4T1 tumor line were evaluated by the cell viability test MTT, and the IC 50% values were 40mM and 20mM in the 24 and 48 hour, respectively. With the empty DODAC treatment in the 4T1 cells the IC 50% was 0.5 mM and 0.09 at the 6 and 12 hour respectively and with the treatment of DODAC/FOS at IC50% of 0.78 mM at 6 hours and 0.17 mM in 12 hours of treatment. The production of lipoperoxidized free radicals was evaluated by the formation of TBARS in 4T1 cells, treated for 24 hours with Pho-s, showing a significant difference from 30mM and 1.6mM with empty DODAC, with no statistical difference in the DODAC/FOS group . Changes in the cell population distributions in the cell cycle phases evaluated by flow cytometry showed an increase in fragmented DNA after 12 and 24 hours and decrease in the other phases of the cycle. Alterations in the cellular arrangements were evaluated by means of the labeling with the fluorochromes acridine-orange and rhodamine 123 by laser confocal microscopy, in which the change in morphology, membrane fragmentation and loss of the projection of cytoplasmic prolongations were observed. The induction of senescence cells was evaluated by enzymatic activity with beta-galactosidase enzyme, showing senescent cells only at the concentration of 20 mM. The apoptotic activity of breast tumor cells was evaluated by Annexin V / PI, showing an increase, mainly, of late apoptosis in all treatments. Several control markers and cell cycle progression, stress, angiogenesis and hormone receptors and mitochondrial potential were evaluated by flow cytometry. The results showed an increase in the expression of the proteins bound with apoptosis and cell death and general decrease of the proteins that participate in the processes of cell cycle progression and cell proliferation, in addition to the anti-apoptotic proteins, which demonstrates its antitumoral potential
67

Atividade anticâncer de quercetina, narigina, morina e acetoxi DMU no tratamentos terapêutico de ratos inoculados com carcinossarcoma de Walker 256 / Anticancer activity of quercetin, naringenin, and morin Acetoxy DMU in the therapeutic treatment of rats inoculated with Walker 256 carcinosarcoma

Camargo, Camila de Andrade, 1980- 08 August 2011 (has links)
Orientadores: Hiroshi Aoyama / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-19T03:25:44Z (GMT). No. of bitstreams: 1 Camargo_CamiladeAndrade_D.pdf: 5871656 bytes, checksum: 08f82cc2064fb3997898335664c62806 (MD5) Previous issue date: 2011 / Resumo: Atualmente o câncer é um problema de saúde pública mundial, em virtude do aumento de sua incidência. A anorexia e a perda de peso involuntária são comuns em pacientes oncológicos. Esta condição, também conhecida como caquexia, afeta a capacidade funcional, a resposta ao tratamento, a qualidade de vida e a sobrevida do paciente. Estima-se que aproximadamente dois milhões de pessoas no mundo morrem anualmente devido às conseqüências da via câncer/caquexia. O modelo estudado neste trabalho é o carcinossarcoma de Walker 256 (W256), que tem como característica principal o desenvolvimento da caquexia nos animais portadores, devido ao seu comportamento biológico agressivo, crescimento invasivo e alto potencial de metástase. Os flavonóides, fitocompostos polifenólicos encontrados em plantas, apresentam diversas atividades biológicas, principalmente, devido as suas propriedades antioxidantes e habilidades em modular diversas enzimas ou receptores celulares. Estes compostos possuem efeitos protetores contra doenças relacionadas ao sistema cardiovascular, certas etiologias de câncer, doenças provocadas pela fotossensibilidade e envelhecimento, dentre outras. A proposta do presente estudo foi avaliar os efeitos dos flavonóides quercetina, narigina, morina e do composto acetoxi DMU (um derivado sintético do resveratrol e do DMU-212), na prevenção/atenuação da caquexia e inibição do crescimento do tumor em ratos portadores de W256, num estudo pré-clínico. Ratos machos sadios foram inoculados subcutaneamente, no flanco direito, com as células tumorais e tratados com diferentes doses dos compostos (10, 25 e 35mg/kg), via intraperitoneal, 5 dias consecutivos por semana, durante 50 dias ou até o óbito. A administração de 10mg/kg de quercetina e de 25mg/kg de narigina, morina e do composto acetoxi DMU inibiram cerca de 50% o crescimento do tumor (ED50) quando comparado com os animais controle inoculados com tumor, sem tratamento (grupo Tumor). A ED50 para os tratamentos com quercetina, narigina, morina e acetoxi DMU foi responsável por um aumento de 30, 70, 60 e 70%, respectivamente, na sobrevida dos ratos tratados (p < 0,05) em contraste aos 100% de mortalidade observada no grupo Tumor. Outra conseqüência da administração da ED50 foi a ocorrência de regressão tumoral em 2, 5, 2 e 3 animais, respectivamente, para os tratamentos com quercetina, narigina, morina e acetoxi DMU (n=10). O tratamento com os compostos também foi eficiente em manter os níveis das citocinas TNF-? e IL-6 (no tecido hepático e tumoral do hospedeiro), mediadores do processo caquético, semelhantes aos encontrados nos ratos controle sem tumor (grupo Controle). Já os ratos do grupo Tumor apresentaram altos níveis destas citocinas, tanto nas amostras de fígado como nas de tumor. Os tratamentos promoveram também um alto potencial anti-angiogênico, mostrado através da diminuição na expressão de VEGF e nas atividades das MMP-2 presentes nas amostras de fígado e tumor. Os níveis de VEGF encontrados nos fígados dos ratos do grupo Tumor foram significantemente maiores que os do grupo Controle. Outro efeito do tratamento com os compostos foi uma diminuição significativa na expressão da proteína tirosina fosfatase de baixa massa molecular (nas amostras de fígado e tumor), que havia sido super-expressa em animais do grupo Tumor. As análises dos pesos dos testículos e órgãos reprodutivos acessórios (epidídimo, vesícula seminal, glândula de coagulação e próstata) foram feitas para os animais tratados com narigina e acetoxi DMU. Os resultados indicaram uma redução significativa nos órgãos dos animais do grupo Tumor em comparação com o grupo Controle. Pelo contrário, o tratamento terapêutico de ratos com tumor com a narigina e o acetoxi DMU se mostrou eficaz em proteger a morfologia destes órgãos e inibir esta redução. De acordo com os resultados obtidos, o melhor tratamento foi obtido com o acetoxi DMU. Os resultados obtidos neste trabalho confirmam o efeito dos flavonóides e de acetoxi DMU em diminuir os sintomas da caquexia no modelo tumoral utilizado para experimentação e em inibir o crescimento tumoral, contribuindo, assim, para uma melhor compreensão da ação in vivo destes compostos, tanto no organismo sadio como na presença do tumor / Abstract: Currently, cancer is a public health problem worldwide in virtue of the increase in incidence. Anorexia and involuntary weight loss are common in cancer patients. This condition, also known as cachexia, affects the functional capacity, response to treatment, quality of life and patient survival. It is estimated that approximately two million people worldwide die annually because of cancer cachexia consequences. In this work the Walker 256 carcinosarcoma (W256) is used as an experimental model to establish cancer cachexia in infected animals. Furthermore, it presents an aggressive biological behavior, local invasive growth and high metastasis potential. Flavonoids are polyphenolic compounds with several biological activities mainly due to its antioxidant properties and ability to modulate several enzymes or cellular receptors. These characteristics are associated with the protective effect attributed to these compounds against cardiovascular system diseases, some causes of cancer, diseases caused by photosensitivity and aging, among other. The aim of this study was to evaluate the effects of the flavonoids quercetin, naringin and morin and the compound acetoxy DMU (a synthetic derivative of resveratrol and DMU-212) in the cachexia prevention/attenuation and inhibition of tumor growth in rats bearing W256, in a preclinical study. Healthy male rats were inoculated with tumor cells and treated with different doses of quercetin, naringin, morin and acetoxy DMU (10, 25 and 35mg/kg) intraperitoneally administered, 5 consecutive times a week, during 50 days or until death. The administration of 10 mg/kg quercetin and 25mg/kg naringin, morin and acetoxy DMU inhibited about 50% of tumor growth (ED50) compared with Tumor group (untreated). The ED50 values for the treatment with quercetin, naringin, morin and acetoxy DMU were responsible for a survival increase about 30, 50, 40 and 60%, respectively, in contrast to 100% mortality observed in the tumor group. Another consequence of the ED50 administration was the tumor regression in 2, 5, 2 and 3 animals, respectively, for treatment with quercetin, naringin, morin and acetoxy DMU (n=10). The effect of treatment with these compounds on cytokines mediators of the cachectic process (in liver and tumor tissue) was efficient in maintaining the TNF-? and IL-6 levels similar to those found in control rats (Control group). Tumor group presented high levels of these cytokines in both liver and tumor samples. The treatments also promoted a high potential anti-angiogenic, shown by the decrease in VEGF expression and MMP-2 activity of liver and tumor samples. The VEGF levels found in Tumor group (liver samples) were significantly higher than the Control group. Another effect of treatment with the compounds was a significant decrease in the low molecular weight protein tyrosine phosphatase expression (in liver and tumor tissue), which had been over-expressed in Tumor group. Analyses of testes and accessory reproductive organs weights (epididymis, seminal vesicle, coagulating gland and prostate) were made for animals treated with narigina and acetoxy DMU. The results indicated a significant reduction in Tumor group organs compared with the Control group. On the other hand, the naringin and acetoxi DMU therapeutic treatments of rats with tumor have been proven effective in protecting the morphology of these organs and inhibiting its reduction. According to the results, the best treatment was obtained with the acetoxy DMU. The results of this work confirm the effect of these flavonoids and acetoxi DMU on reducing the cachexia symptoms and tumor growth inhibition, contributing to a better understanding of the action of these compounds in vivo, both in healthy and in tumor organisms / Doutorado / Bioquimica / Doutor em Biologia Funcional e Molecular
68

Classification of polyphenolic compounds according to their differential effects on two breast cancer cell lines by FTIR spectroscopy

Mignolet, Alix 22 February 2017 (has links)
The development of reliable and cost-saving methods to select pre-clinically new potential drugs with unknown and original mechanisms of action for cancer therapy has become crucial. Previous investigations demonstrated that infrared spectra of cancer cells exposed to well-known anticancer drugs used in the clinics provide a global fingerprint of all the metabolic modifications induced. Nowadays several natural products have been recognized for their medicinal values. Polyphenolic compounds constitute one of the largest groups of plant metabolites and many studies have demonstrated their anticancer properties at multiple steps of carcinogenesis. Taking into account the large diversity of polyphenolic structures in nature and their numerous targets against carcinogenesis, the step of selection becomes essential as it is virtually impossible to classify them using traditional classification techniques. While FTIR spectroscopy appears to have a definite potential to sort anticancer drugs on the basis of the metabolic modifications they induced, the present challenge in this thesis is to evaluate the drug-induced spectral changes in cancer cells on a larger scale. The coupling of FTIR spectroscopy with a high throughput screening extension could become a useful method to generate drug classifications based on the “modes of action”. In a first step, the IC50 was evaluated for each polyphenol to normalize all spectral experiments that will be carried out on breast cancer cells. The first experiments revealed dispersive artifacts (wide variations of absorbance distribution and Mie scattering effects) contributing to spectral measurements. To minimize them, the best option was covering uniformly the surface of spectral measurement with cells (detailed in chapter III). Once the protocol refined, it was applied to the study of MDA-MB-231 breast cancer cells exposed for 24 hrs to 15 polyphenols. Through unsupervised and supervised statistical analyses, a distinction between polyphenol treatments could be well established. Complex effects of polyphenols on cancer cells were revealed, suggesting that mechanisms specific to each polyphenol were evidenced by the whole infrared spectrum. Clustering of polyphenol-induced spectral signatures by Hierarchical Cluster Analysis indicates that some of the polyphenols share similar effects on MDA-MB-231 (detailed in chapter IV). This experiment was then extended to another breast cancer cell line, MCF-7. It demonstrated a cell line dependency to polyphenolic treatments. Finally a subcellular investigation of treated MCF-7 breast cancer cells in their live state was done using Raman imaging. A distinction between nucleus and cytoplasm of treated cells brought supplementary information regarding the effect of polyphenols, leading to subcellular biological assumptions on polyphenol effects. These results paves the way for a new classification based on infrared spectral signatures that reflect the overall chemical modifications experienced by the cells when exposed to drugs. / Le développement de méthodes fiables et peu cher pour sélectionner de potentiels nouveaux médicaments présentant un mécanisme d’action original et inconnu avant toute étape clinique devient crucial. De précédentes études ont pu démontrer que les spectres infrarouges de cellules cancéreuses exposées à des agents anticancéreux connus et utilisé dans le monde clinique fournissent une empreinte globale de toutes les modifications métaboliques induites. La spectroscopie infrarouge est un outil innovant qui semble prometteur pour offrir un aperçu global des processus biologiques et physiologiques qui sont menés par un médicament dans des cellules cancéreuses. De nos jours, de nombreux produits naturels ont été reconnus pour leurs propriétés médicinales. Les polyphénols constituent l’un des plus vastes groupes de métabolites végétaux et de nombreuses études ont démontré leurs propriétés anticancéreuses à de multiples étapes de la carcinogénèse. En prenant en compte la très grande diversité de structures polyphénoliques existantes dans la nature et leurs nombreuses cibles anti-tumorales, l’étape de sélection est devenue essentielle comme il est virtuellement impossible de les classifier grâce à des techniques de classification traditionnelles telles que les études –omiques. Dès lors, le défi de cette thèse est d’évaluer les variations spectrales induites par un polyphénol dans des cellules cancéreuses à une plus grande échelle. Le couplage de la spectroscopie IRTF avec une extension de criblage de haut débit pourrait devenir une méthode utile pour générer des classifications de molécules sur base de leur « modes d’action ». Dans un premier temps, la concentration qui inhibe 50% de la croissance des cellules cancéreuses fut déterminée pour chaque polyphénol et chaque lignée de cellules cancéreuses. Le traitement des cellules à cette concentration permet une normalisation interne des expériences réalisées ultérieurement en spectroscopie infrarouge. Une fois le protocole établi, la lignée MDA-MB-231 fut exposée durant 24 heures à 15 polyphénols différents. Au moyen d’analyses statistiques multivariées supervisées et non supervisées, une distinction parmi les polyphénols a pu être établie et des effets complexes des polyphénols sur les cellules cancéreuses ont pu être révélés, suggérant des mécanismes d’action spécifiques à chaque polyphénol mis en évidence par spectroscopie infrarouge. Finalement, une étude subcellulaire sur cellules vivantes fut réalisée par imagerie Raman sur une seconde lignée de cellules cancéreuses mammaires appelées MCF-7. Cela permis de compléter en partie l’information macroscopique offerte par la spectroscopie infrarouge par une information microscopique sur l’effet de certains polyphénols. Cette thèse a ouvert la voie pour de nouvelles techniques de classification d’agents anticancéreux basées sur la spectroscopie infrarouge, technique sensible à l’ensemble des modifications chimiques subies par des cellules. / Option Chimie du Doctorat en Sciences / info:eu-repo/semantics/nonPublished
69

Cooperative Drug Combinations Target Oncogenes and Tumor Suppressors in Cancer

Tyler John Peat (11790659) 19 December 2021 (has links)
<p>Multiple myeloma (MM) is a neoplasm involving plasma cells in the bone marrow. Drug resistance and progression are common, underscoring the need for new drug combinations. Utilizing a high-throughput screen of tool compounds to limit gro­­­­wth of human MM cell lines and <i>i</i><i>n silico</i> robust regression analysis of drug responses, potential synergistic combinations were identified. Further selection of effective combinations that reduce oncogenic MYC expression and enhance tumor suppressor p16 activity was based on earlier genetic and drug studies that identified MYC and p16 as appropriate targets in MM. Furthermore, the top three combinations synergistically reduced drug sensitive and resistant cell viability <i>in vitro</i> and the were effective in <i>ex vivo</i> treated patient cells Combination-associated survival was also prolonged in a transplantable Ras-driven allograft model of advanced MM that closely recapitulates MM in humans. One top drug combination was selected for further preclinical development. Targets, mechanism of action, and efficacy of the combination were evaluated through several <i>in vitro</i> and <i>in vivo </i>models, as well as <i>ex vivo</i> in myeloma patient cells. Effective targeting of the combination resulted in synergistic inhibition of proteasome inhibitor (PI) sensitive MM cells, as well as cell with induced PI resistance. Additionally, the combination was effective at delaying L363 MM xenograft growth in NSG mice and prolonging survival compared to single agent therapy. Finally, a cooperative signature of combined targeting was elucidated via RNA sequencing. These data identify potentially useful drug combinations for preclinical evaluation in drug-resistant MM and may ultimately reveal novel mechanisms of combined drug sensitivity.</p>
70

DEVELOPING IN-VITRO SYNTHETIC BLOOD CLOT MODELS FOR TESTING THROMBOLYTIC DRUGS

Ziqian Zeng (12441402) 21 April 2022 (has links)
<p>  </p> <p>Thrombosis is the pathological formation of a blood clot in the body that blocks blood circulation, leading to high morbidity and mortality rates. Thrombolytic drugs that offer rapid clot dissolution are promising treatments yet current drugs are often associated with limited efficacy and high bleeding risks. While numerous animal thrombosis models have been developed for drug screening, the translation of therapeutic agents into and through clinical trials remains limited. This is largely due to animal models’ poor reproducibility and distinctive physiology to that of humans. <em>In-vitro</em> flow models that utilize both human blood components and physiologically relevant flow conditions can provide for a more representative testing environment to screen thrombolytic drugs. Developing better <em>in-vitro</em> models may not eliminate the need for preclinical animal testing but can help exclude inefficient agents earlier in the drug development pipeline to expedite the drug evaluation process. Existing <em>in-vitro</em> thrombolysis flow models are not ideal as they either adopt over-simplified clot substrates or utilize small-length-scale geometries that insufficiently mimic native hemodynamics. Thus, we propose to first develop a static fluorescently labeled clot lysis assay for an initial high throughput screening of thrombolytic drugs, and ultimately engineer a highly reproducible, physiological scale, flowing clot lysis model for more human relevant drug efficacy evaluation. Developing the static clot lysis assay not only helps to understand the mechanism of how diversified clotting conditions affect clot properties but also offer a chance to well-characterize fluorescence conjugations to fibrins. The ultimate flow model combines an <em>in-vivo</em>-like fluorescence incorporated synthetic clot (FISC) and a human-relevant flow system. Guided by results from static clotting experiments diversified FISCs are fluorescently optimized and fabricated dynamically using a Chandler loop setup at various conditions. The flow system is a tubing-based structure that comprises of a peristaltic pump, and a well-controlled flow chamber to provide for physiological shear and pulsatile levels. Therefore, the proposed synthetic clot model is a versatile platform that can mimic a variety of thrombosis conditions and offer representative drug testing and dosing results across numerous thrombolytic agents.</p>

Page generated in 0.0776 seconds